The identification of Dyrk1b as a disease gene for abdominal obesity–metabolic syndrome (OMIM AOMS3) provided an exceptional opportunity to explore the underlying disease mechanisms and for the discovery of drug targets for a disorder that has one of the fastest growing incidences. This evidence concerns the gene DYRK1B and metabolic syndrome.